

USSN 09/405,499
Filed September 23, 1999
Preliminary Amendment
Attorney Docket: 05213-0640 (43170-219680)

Amendments T The Claims
(Clean Version)

52. An endostatin protein consisting of a fragment of a NC1 region of a collagen protein, wherein the fragment inhibits angiogenesis.

USSN 09/405,499
Filed September 23, 1999
Preliminary Amendment
Attorney Docket: 05213-0640 (43170-219680)

Pending Claims (for reference only)

52.(Twice Amended) An endostatin protein consisting of a fragment of a NC1 region of a collagen protein, wherein the fragment inhibits angiogenesis.

53.(Amended) The protein of Claim 52, wherein the protein is a fragment of a non-fibrillar collagen protein.

54.(Amended) The protein of Claim 52, wherein the protein is a fragment of a collagen type XVIII protein.

55.(Amended) The protein of Claim 52, wherein the protein is a fragment of a collagen type XV protein.

57.(Amended) The protein of Claim 52, wherein the protein is produced recombinantly.

58.(Amended) The protein of Claim 52, wherein the protein is naturally occurring.

59.(Amended) The protein of Claim 52, wherein the protein is human.

60.(Amended) The protein of Claim 52, wherein the protein inhibits angiogenesis *in vivo*.

61.(Amended) The protein of Claim 52, wherein the protein inhibits angiogenesis *in vitro*.

62.(Amended) The protein of Claim 52, wherein the protein has an N-terminal amino acid sequence as shown in SEQ ID NO:1.

63.(Amended) A composition comprising, an endostatin protein combined with an angiostatin protein, wherein the endostatin protein consists of a fragment of a NC1 region of a collagen protein, wherein the angiostatin protein is a fragment of a kringle region of plasminogen

USSN 09/405,499
Filed September 23, 1999
Preliminary Amendment
Attorney Docket: 05213-0640 (43170-219680)

and wherein the endostatin protein and the angiostatin protein are further characterized by their ability to inhibit angiogenesis.

64. The composition of Claim 63, wherein the endostatin protein is a fragment of a non-fibrillar collagen protein.

65. The composition of Claim 63, wherein the endostatin protein is a fragment of a collagen type XVIII protein.

66. The composition of Claim 63, wherein the endostatin protein is a fragment of a collagen type XV protein.

68. The composition of Claim 63, wherein the endostatin protein and angiostatin protein are produced recombinantly.

69. The composition of Claim 63, wherein the endostatin protein and angiostatin protein are naturally occurring.

70. The composition of Claim 63, wherein the endostatin protein and angiostatin protein are human.

71. The composition of Claim 63, wherein the endostatin protein and angiostatin protein inhibit angiogenesis *in vivo*.

72. The composition of Claim 63, wherein the endostatin protein and angiostatin protein inhibit angiogenesis *in vitro*.

73. The composition of Claim 63, wherein the endostatin protein has an N-terminal amino acid sequence as shown in SEQ ID NO: 1.